Quest Diagnostics (DGX) Tops Q4 EPS by 4c; Guides In-Line
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St set for tepid open as oil prices fall, Treasury yields rise
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Quest Diagnostics (DGX) PT Raised to $96 at Jefferies Following 4Q Earnings Report
January 27, 2017 9:03 AM ESTJefferies raised its price target on Quest Diagnostics (NYSE: DGX) to $96.00 (from $86.00) while maintaining a Hold rating. DGX posted its 5th consecutive quarter of positive organic volume growth, which yielded a $0.04/3% EPS beat on in-line EBITDA.
Analyst Brian Tanquilut commented, "We... More
